Rate My Professor La Wei

Dr. Wei's academic interests focus on biostatistical methods for clinical trials, including design, analysis, and interpretation in oncology. Key areas encompass survival analysis, biomarker evaluation, adaptive trial designs, phase I/II studies, and applications in non-small cell lung cancer, neuroendocrine neoplasms, immune checkpoint inhibitors, and drug combinations. He has authored or co-authored over 330 publications, with more than 7,100 citations. Selected key publications include: "CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer" (2026); "Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer" (2025); "Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors" (2025); "DrugCombo: an informatics bridge for anticancer drug combination Phase I trial design" (2025); "A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms (NEN): updated overall survival data" (2023); and "Phase 2 study of umbralisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma" (earlier phase 2 trial contributions). Dr. Wei oversees clinical trials division activities, providing expertise in oncology biostatistics and population health analytics.